首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1746585

日本生物相似藥市場報告（按分子、適應症、製造類型和地區）2025-2033

Japan Biosimilar Market Report by Molecule, Indication, Manufacturing Type, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本生物相似藥市場規模達4.758億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到34.196億美元，2025-2033年期間的複合年成長率（CAGR）為22.7%。慢性病盛行率的上升、政府簡化核准的措施、人口老化的需求、製藥公司的大力參與、成本控制措施、認知度的提高以及產品線的不斷擴展，是推動市場發展的一些關鍵因素。

生物相似藥是一種與現有的、已核准的參考生物製劑高度相似且無臨床意義差異的生物製品。與小分子學名藥（與品牌藥完全相同）相比，生物相似藥是源自生物體的大型複雜分子，例如蛋白質或抗體。生物相似藥的開發涉及與參考生物製劑的全面比較，涵蓋結構、功能和功效等方面。由於生物製劑固有的複雜性，不可能生產出完全相同的複製品；然而，透過嚴格的測試和法規核准流程，生物相似藥在安全性和功效方面已被證明與參考生物製劑高度相似。生物相似藥提供了一種比昂貴生物製劑更經濟實惠的替代品，並在全球範圍內作為應對醫療成本上漲的一種手段而備受推崇，它為醫療系統、從業人員和患者提供了既經濟實惠又不損害治療效果的治療方案。

日本生物相似藥市場趨勢：

癌症和糖尿病等慢性病的日益流行，使得具有成本效益的治療方案成為必要，這主要推動了日本生物相似藥市場的成長。同時，日本政府推動使用生物相似藥的舉措以及引入監管框架以加快核准流程，大大推動了市場的成長。此外，日本老年人口的增加凸顯了對生物相似藥等可負擔得起的醫療保健解決方案的需求，從而加強了市場的成長。除此之外，大批老牌製藥公司在生物相似藥研發 (R&D) 方面的大力投資，正在為市場成長提供動力，因為這些公司利用其專業知識和資源來加快生物相似藥產品的生產和商業化。同時，國內外製藥公司之間的廣泛合作與夥伴關係刺激了創新，拓寬了生物相似藥產品的範圍，這有助於市場的成長。此外，受經濟因素驅動，日本對醫療成本控制的追求進一步提振了生物相似藥市場，因為這些產品提供了一種在不影響療效的情況下大幅節省成本的途徑。此外，醫療專業人員和患者對生物相似藥的認知度和接受度不斷提高，對這些替代方案形成了積極的認知，這為市場擴張帶來了豐厚的利潤。此外，對個人化醫療和標靶治療的日益重視，以及涵蓋眾多治療領域的生物相似藥產品線的不斷擴展，也為市場成長創造了積極的前景。

日本生物相似藥市場細分：

分子洞察：

英夫利西單抗
甘精胰島素
依泊汀阿爾法
依那西普
非格司亭
生長激素
利妥昔單抗
促卵泡激素阿爾法
阿達木單抗
培非格司亭
曲妥珠單抗
貝伐單抗
其他

指示見解：

自體免疫疾病
血液疾病
糖尿病
腫瘤學
生長缺陷
女性不孕症
其他

製造類型洞察：

內部製造
合約製造

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本生物相似藥市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物相似藥市場有何影響？
日本生物相似藥市場依分子分類是怎樣的？
日本生物相似藥市場根據適應症的分類是怎樣的？
根據製造類型，日本生物相似藥市場是如何分類的？
日本生物相似藥市場的價值鏈分為哪些階段？
日本生物相似藥的關鍵促進因素和挑戰是什麼？
日本生物相似藥市場的結構是怎麼樣的？主要參與者是誰？
日本生物相似藥市場的競爭程度如何？

本報告回答的關鍵問題：

日本生物相似藥市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本生物相似藥市場有何影響？
日本生物相似藥市場依分子分類是怎樣的？
日本生物相似藥市場根據適應症的分類是怎樣的？
根據製造類型，日本生物相似藥市場是如何分類的？
日本生物相似藥市場的價值鏈分為哪些階段？
日本生物相似藥的關鍵促進因素和挑戰是什麼？
日本生物相似藥市場的結構是怎麼樣的？主要參與者是誰？
日本生物相似藥市場的競爭程度如何？

Japan biosimilar market size reached USD 475.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,419.6 Million by 2033, exhibiting a growth rate (CAGR) of 22.7% during 2025-2033. The increasing chronic disease prevalence, government initiatives for streamlined approvals, aging population demands, strong pharmaceutical company involvement, cost containment efforts, heightened awareness, and expanding product pipelines represent some of the key factors driving the market.

A biosimilaris a biological product that is highly similar to and has no clinically meaningful differences from an existing, already approved reference biologic drug. Compared to generic versions of small-molecule drugs, which are identical replicas of their branded counterparts, biosimilars are large, complex molecules derived from living organisms, such as proteins or antibodies. The development of biosimilars involves a comprehensive comparison with the reference biologic, encompassing aspects like structure, function, and efficacy. Due to the inherent complexity of biologics, it is impossible to produce exact replicas; however, biosimilars are demonstrated to be highly similar in terms of safety and efficacy through rigorous testing and regulatory approval processes. Biosimilars offers a more affordable alternative to expensive biological drug and have gained prominence globally as a means to address the rising costs of healthcare, providing healthcare systems, practitioners, and patients with cost-effective options without compromising therapeutic benefits.

Japan Biosimilar Market Trends:

The increasing prevalence of chronic diseases, such as cancer and diabetes, necessitating cost-effective treatment options is primarily driving the growth of the Japan biosimilar market. In line with this, the Japanese government's initiatives to promote the use of biosimilars, and the introduction of a regulatory framework to expedite the approval process, are significantly fueling the market growth. Moreover, the rising geriatric population in Japan underscores the demand for affordable healthcare solutions, such as biosimilars, strengthening the market growth. Besides this, the strong presence of established pharmaceutical companies investing in biosimilar research and development (R&D) is providing an impetus to the market growth as these companies leverage their expertise and resources to expedite the production and commercialization of biosimilar products. Concurrently, extensive collaborations and partnerships between domestic and international pharmaceutical firms stimulate innovation and widen the scope of biosimilar offerings, which is contributing to the market's growth. Along with this, the push for healthcare cost containment, driven by economic factors, further bolsters the biosimilar market in Japan, as these products provide an avenue for achieving significant cost savings without compromising on treatment efficacy. Additionally, the increasing awareness and acceptance of biosimilars among healthcare professionals and patients, fostering a positive perception of these alternatives, is presenting lucrative opportunities for the market expansion. Furthermore, the growing emphasis on personalized medicine and targeted therapies and the expanding pipeline of biosimilar products encompassing a diverse range of therapeutic areas are creating a positive outlook for the market growth.

Japan Biosimilar Market Segmentation:

Molecule Insights:

Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Pegfilgrastim
Trastuzumab
Bevacizumab
Others

Indication Insights:

Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Others

Manufacturing Type Insights:

In-House Manufacturing
Contract Manufacturing

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan biosimilar market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biosimilar market?
What is the breakup of the Japan biosimilar market on the basis of molecule?
What is the breakup of the Japan biosimilar market on the basis of indication?
What is the breakup of the Japan biosimilar market on the basis of manufacturing type?
What are the various stages in the value chain of the Japan biosimilar market?
What are the key driving factors and challenges in the Japan biosimilar?
What is the structure of the Japan biosimilar market and who are the key players?
What is the degree of competition in the Japan biosimilar market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biosimilar Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biosimilar Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Biosimilar Market - Breakup by Molecule

6.1 Infliximab
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Insulin Glargine
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Epoetin Alfa
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Etanercept
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Filgrastim
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Somatropin
- 6.6.1 Overview
- 6.6.2 Historical and Current Market Trends (2019-2024)
- 6.6.3 Market Forecast (2025-2033)
6.7 Rituximab
- 6.7.1 Overview
- 6.7.2 Historical and Current Market Trends (2019-2024)
- 6.7.3 Market Forecast (2025-2033)
6.8 Follitropin Alfa
- 6.8.1 Overview
- 6.8.2 Historical and Current Market Trends (2019-2024)
- 6.8.3 Market Forecast (2025-2033)
6.9 Adalimumab
- 6.9.1 Overview
- 6.9.2 Historical and Current Market Trends (2019-2024)
- 6.9.3 Market Forecast (2025-2033)
6.10 Pegfilgrastim
- 6.10.1 Overview
- 6.10.2 Historical and Current Market Trends (2019-2024)
- 6.10.3 Market Forecast (2025-2033)
6.11 Trastuzumab
- 6.11.1 Overview
- 6.11.2 Historical and Current Market Trends (2019-2024)
- 6.11.3 Market Forecast (2025-2033)
6.12 Bevacizumab
- 6.12.1 Overview
- 6.12.2 Historical and Current Market Trends (2019-2024)
- 6.12.3 Market Forecast (2025-2033)
6.13 Others
- 6.13.1 Historical and Current Market Trends (2019-2024)
- 6.13.2 Market Forecast (2025-2033)

7 Japan Biosimilar Market - Breakup by Indication

7.1 Auto-Immune Diseases
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Blood Disorder
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Diabetes
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Oncology
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Growth Deficiency
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2019-2024)
- 7.5.3 Market Forecast (2025-2033)
7.6 Female Infertility
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2019-2024)
- 7.6.3 Market Forecast (2025-2033)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2019-2024)
- 7.7.2 Market Forecast (2025-2033)

8 Japan Biosimilar Market - Breakup by Manufacturing Type

8.1 In-House Manufacturing
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Contract Manufacturing
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
- 8.2.3 Market Forecast (2025-2033)

9 Japan Biosimilar Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Biosimilar Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis